Cognitive & Mood NeuropeptideNot FDA-approved · research compound

Cerebrolysin

FPF 1070 · FPE 1070 · Cere

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

5-30mL – 5-10 mL IM daily

Neurotrophic

Cerebrolysin is a porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids obtained by standardized enzymatic breakdown of purified pig brain proteins. Manufactured by EVER Neuro Pharma (Austria), it has been used clinically for over 40 years, primarily in Europe, Asia, and Latin America, for the treatment of neurological conditions including stroke, traumatic brain injury, and dementia.

Quick Start

Route

Intramuscular (IM)

Start low

5-30mL IM

Frequency

daily

Timing

No specific requirement

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

5-30mL · Intramuscular (IM) · daily

conservative starter

5-30mL

daily

Expert

Neuro-Recovery Phase

5-10 mL · IM · Daily

human clinical trial · Alvarez et al. 2006 (Eur J Neurol)

Large volume requires intramuscular injection. Highly neurotrophic pig-brain derived peptide mix.

5-10 mL

Daily

◆

How it works

Contains peptide fragments that mimic neurotrophic factors (BDNF, NGF, CNTF, GDNF-like activity), activating neuronal survival pathways including PI3K/Akt and MAPK/ERK signaling cascades.

Promotes neuroplasticity by enhancing dendritic sprouting, synaptogenesis, and long-term potentiation (LTP) in hippocampal and cortical neurons.

Exerts neuroprotective effects by reducing excitotoxicity, oxidative stress, and neuroinflammation. May inhibit calpain-mediated neuronal damage and reduce apoptotic cell death after ischemic insult.

What to expect

Early

Days 1–7

Days 1-7: Generally well tolerated with minimal immediate effects. Some patients report improved alertness or mental energy within the first week.

Evidence

HumanPresent

AnimalStrong

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Mechanism/class: parenteral porcine brain-derived Cerebrolysin has pharmacodynamic properties similar to endogenous neurotrophic factors.

Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors.

Cerebrolysin: a review of its use in dementia. Drugs & aging · 2009 · PMID 19848437

Evidence scope. Narrative review of dementia trials; exact proprietary porcine peptide preparation and parenteral route, but not an IM dose claim.

Primary safety in dementia trials: Cerebrolysin was generally well tolerated, with dizziness or vertigo the most frequently reported adverse event.

Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) being the most frequently reported adverse event.

Cerebrolysin: a review of its use in dementia. Drugs & aging · 2009 · PMID 19848437

Evidence scope. Narrative review of randomized dementia trials lasting up to 28 weeks; parenteral treatment, route not further separated into IM versus IV in the quoted sentence.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Exact dose/route: 5-30 mL intramuscularly daily. Checked abstracts reported 30-50 mL parenterally once daily in stroke or 30 mL/day in Alzheimer trials, but did not verify the page’s full 5-30 mL IM regimen.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

NAD+ InjectableNo direct conflict - NAD+ supports cellular energy while Cerebrolysin provides neurotrophic signaling

Injectable B-ComplexB vitamins support neurological function - administer in separate syringes on same day

BPC-157No pharmacological conflict - different tissue targets and mechanisms

PinealonBoth support neurological function through different mechanisms - no known interaction

Keep separate

Any compound in same syringeCerebrolysin is a complex biological mixture - must be administered alone, never mixed with other compounds in the same syringe

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Pharmacokinetics

Illustrative plasma concentration · 17 h

Half-life

Minutes (complex mixture - individual peptide components have varying kinetics)

Peak · Tmax

~30-60 min

IM, immediate IV

Elimination

~2-4 hours

Peptide components

Bioavailability

~100%

IM/IV

Duration of action

24-48 hours

Neurotrophic signaling cascades persist; cumulative neuroplastic effects build over days

Clearance

Enzymatic degradation (peptidases); renal excretion of amino acid fragments

Storage. Store refrigerated at 2-8C. Protect from light. Do not freeze.

Regulatory status

Approved for clinical use in over 45 countries (including Austria, Germany, Russia, China, South Korea, and many Latin American nations). Not FDA-approved in the United States. Classified as a prescription pharmaceutical in approved markets.

Put it to work

Calculate, log & track

Open Cerebrolysin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Cerebrolysin in the app →

Go deeper

The guide & community

The complete Cerebrolysin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community